<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ROBAXIN - methocarbamol tablet, film coated </strong><br>STAT RX USA LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">robaxin<span class="Sup">®</span>/robaxin<span class="Sup">®</span>-750 (methocarbamol tablets, USP), a carbamate derivative of 
guaifenesin, is a central nervous system (CNS) depressant with sedative and 
musculoskeletal relaxant properties.</p>
<p>The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 
1-carbamate and has the empirical formula C<span class="Sub">11</span>H<span class="Sub">15</span>NO<span class="Sub">5</span>. Its molecular weight is 241.24. 
The structural formula is shown below.</p>
<br><p><img alt="Structure Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5666ece8-9a10-4dcc-a7dc-3cd29df10e28&amp;name=robaxin-tablets-01.jpg"></p>
<p>Methocarbamol is a white powder, sparingly soluble in water and chloroform, 
soluble in alcohol (only with heating) and propylene glycol, and insoluble in 
benzene and <span class="Italics">n</span>-hexane. </p>
<p>robaxin<span class="Sup">® </span>is available as a light orange, round, 
film-coated tablet containing 500 mg of methocarbamol, USP for oral 
administration. The inactive ingredients present are corn starch, FD and C 
Yellow 6, hydroxypropyl cellulose, hypromellose, magnesium stearate, polysorbate 
20, povidone, propylene glycol, saccharin sodium, sodium lauryl sulfate, sodium 
starch glycolate, stearic acid, titanium dioxide. </p>
<p>robaxin<span class="Sup">®</span>-750 is available as an orange capsule-shaped, 
film-coated tablet containing 750 mg of methocarbamol, USP for oral 
administration. In addition to the inactive ingredients present in robaxin<span class="Sup">®</span>, robaxin<span class="Sup">®</span>-750 also contains D and C 
Yellow 10.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The mechanism of action of methocarbamol in humans has not been 
established, but may be due to general central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. 
It has no direct action on the contractile mechanism of striated muscle, the 
motor end plate or the nerve fiber. </p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Pharmacokinetics</span><p>In healthy volunteers, the plasma clearance of methocarbamol 
ranges between 0.20 and <br>0.80 L/h/kg, the mean plasma elimination half-life 
ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% 
and 50%. </p>
<p>Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation 
of methocarbamol also is likely. Essentially all methocarbamol metabolites are 
eliminated in the urine. Small amounts of unchanged methocarbamol also are 
excreted in the urine.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Special populations<br><br></span><a href="#section-"></a><span class="Italics">Elderly</span><p>The mean (± SD) elimination half-life of methocarbamol in elderly 
healthy volunteers (mean <br>(± SD) age, 69 (± 4) years) was slightly prolonged 
compared to a younger (mean (± SD) age, <br>53.3 (± 8.8) years), healthy 
population (1.5 (± 0.4) hours versus 1.1 (±0.27) hours, respectively). The 
fraction of bound methocarbamol was slightly decreased in the elderly versus 
younger volunteers (41 to 43% versus 46 to 50%, respectively).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Italics"><br>Renally impaired</span><p>The clearance of methocarbamol in 8 renally-impaired patients on 
maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, 
although the mean (± SD) elimination half-life in these two groups was similar: 
1.2 (± 0.6) versus 1.1 (±0.3) hours, respectively.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Italics"><br>Hepatically impaired</span><p>In 8 patients with cirrhosis secondary to <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>, the mean 
total clearance of methocarbamol was reduced approximately 70% compared to that 
obtained in 8 age- and <br>weight-matched normal subjects. The mean (± SD) 
elimination half-life in the cirrhotic patients and the normal subjects was 3.38 
(± 1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of 
methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% 
compared to 46 to 50% in the normal subjects.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 are 
indicated as an adjunct to rest, physical therapy, and other measures for the 
relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions. 
The mode of action of methocarbamol has not been clearly identified, but may be 
related to its sedative properties. Methocarbamol does not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> 
skeletal muscles in man.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 are 
contraindicated in patients hypersensitive to methocarbamol or to any of the 
tablet components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Since methocarbamol may possess a general CNS depressant effect, 
patients receiving robaxin<span class="Sup">® </span>or robaxin<span class="Sup">®</span>-750 should be cautioned about combined effects with alcohol 
and other CNS depressants.</p>
<p>Safe use of robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 has not been established with regard to possible adverse 
effects upon fetal development. There have been reports of fetal and congenital 
abnormalities following in utero exposure to methocarbamol. Therefore, 
robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 should 
not be used in women who are or may become pregnant and particularly during 
early pregnancy unless in the judgment of the physician the potential benefits 
outweigh the possible hazards (see <span class="Bold"><span class="Emphasis"><a href="#section-"> PRECAUTIONS</a>, 
<a href="#section-"> Pregnancy</a></span></span>).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Use In Activities Requiring Mental Alertness</span><p>Methocarbamol may impair mental and/or physical abilities 
required for performance of hazardous tasks, such as operating machinery or 
driving a motor vehicle. Patients should be cautioned about operating machinery, 
including automobiles, until they are reasonably certain that methocarbamol 
therapy does not adversely affect their ability to engage in such activities.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="#section-"></a><span class="Bold"><span class="Bold"><br></span><a href="#section-"></a><br>Information for Patients</span><p class="First">Patients should be cautioned that methocarbamol may cause 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which may impair their ability to operate motor 
vehicles or machinery.</p>
<p>Because methocarbamol may possess a general CNS-depressant effect, patients 
should be cautioned about combined effects with alcohol and other CNS 
depressants.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Drug Interactions</span><p>See <span class="Bold"><span class="Emphasis"><a href="#section-">  WARNINGS</a></span></span> 
and <span class="Bold"><span class="Emphasis"><a href="#section-">  PRECAUTIONS</a></span></span> 
for interaction with CNS drugs and alcohol. </p>
<p>Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, 
methocarbamol should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> 
receiving anticholinesterase agents.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Drug/Laboratory Test Interactions</span><p>Methocarbamol may cause a color interference in certain screening 
tests for <br>5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent 
and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow 
method.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of 
Fertility</span><p>Long-term studies to evaluate the carcinogenic potential of 
methocarbamol have not been performed. No studies have been conducted to assess 
the effect of methocarbamol on mutagenesis or its potential to impair 
fertility.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Pregnancy<br><br></span><span class="Italics">Teratogenic Effects</span><a href="#section-"></a><span class="Italics"><br><br>Pregnancy Category C</span><p>Animal reproduction studies have not been conducted with 
methocarbamol. It is also not known whether methocarbamol can cause fetal harm 
when administered to a pregnant woman or can affect reproduction capacity. 
robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 should 
be given to a pregnant woman only if clearly needed.</p>
<p>Safe use of robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 has not been established with regard to possible adverse 
effects upon fetal development. There have been reports of fetal and congenital 
abnormalities following in utero exposure to methocarbamol. Therefore, 
robaxin<span class="Sup">® </span>and robaxin<span class="Sup">®</span>-750 should 
not be used in women who are or may become pregnant and particularly during 
early pregnancy unless in the judgment of the physician the potential benefits 
outweigh the possible hazards (see <span class="Bold"><span class="Emphasis"><a href="#section-">  WARNINGS</a></span></span>). 
</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Nursing Mothers</span><p>Methocarbamol and/or its metabolites are excreted in the milk of 
dogs; however, it is not known whether methocarbamol or its metabolites are 
excreted in human milk. Because many drugs are excreted in human milk, caution 
should be exercised when robaxin<span class="Sup">® </span>or robaxin<span class="Sup">®</span>-750 is administered to a nursing woman.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Pediatric Use</span><p>Safety and effectiveness of robaxin<span class="Sup">® </span>and 
robaxin<span class="Sup">®</span>-750 in pediatric patients below the age of 16 
have not been established.</p>
<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions reported coincident with the administration of 
methocarbamol include:</p>
<p><span class="Italics">Body as a whole: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span>, 
<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Italics">Cardiovascular system: </span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></p>
<p><span class="Italics">Digestive system: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (including 
<span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">Hemic and lymphatic system: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p>
<p><span class="Italics">Immune system: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></p>
<p><span class="Italics">Nervous system: </span><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, mild muscular 
<span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, sedation, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (including <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>), <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Skin and special senses: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, metallic taste, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Limited information is available on the acute toxicity of 
methocarbamol. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of methocarbamol is frequently in conjunction with 
alcohol or other CNS depressants and includes the following symptoms: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>In post-marketing experience, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 
methocarbamol alone or in the presence of other CNS depressants, alcohol or 
psychotropic drugs.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Treatment</span><p>Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes symptomatic and supportive 
treatment. Supportive measures include maintenance of an adequate airway, 
monitoring urinary output and vital signs, and administration of intravenous 
fluids if necessary. The usefulness of hemodialysis in managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is 
unknown.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">robaxin<span class="Sup">® </span>(methocarbamol), 500 mg – 
Adults:<br>Initial dosage: 3 tablets q.i.d.<br>Maintenance dosage: 2 tablets 
q.i.d.<br>robaxin<span class="Sup">®</span>-750 (methocarbamol): 750 mg – 
Adults:<br>Initial dosage: 2 tablets q.i.d.<br>Maintenance dosage: 1 tablet 
q.4h. or 2 tablets t.i.d.</p>
<p>Six grams a day are recommended for the first 48 to 72 hours of treatment. 
(For severe conditions 8 grams a day may be administered). Thereafter, the 
dosage can usually be reduced to approximately 4 grams a day.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">robaxin<span class="Sup">® </span>(methocarbamol tablets, 
USP)<br>500 mg tablets are light orange, round, film-coated tablets engraved 
with ROBAXIN 500 on the unscored side and SP above the score on the other side. 
They are supplied as follows: </p>
<a name="iecb0e977-3561-428b-80bf-45f0d01e3a40"></a><table width="557">
<col align="left" valign="bottom" width="50%">
<col align="right" valign="bottom" width="50%">
<tbody class="Headless"><tr class="First Last">
<td align="left">Bottles of 100</td>
<td align="right">NDC 0091-7429-63</td>
</tr></tbody>
</table>
<p>robaxin<span class="Sup">®</span>-750 (methocarbamol tablets, USP)<br>750 mg 
tablets are orange, capsule-shaped, film-coated tablets engraved with ROBAXIN 
750 on one side and SP on the other. They are supplied as follows: </p>
<a name="i99740b8a-187a-482f-8483-a8f576386093"></a><table width="566">
<col align="left" valign="bottom" width="50%">
<col align="right" valign="bottom" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">Bottles of 100</td>
<td align="right">NDC 0091-7449-63</td>
</tr>
<tr class="Last">
<td align="left">Bottles of 500</td>
<td align="right">NDC 0091-7449-70</td>
</tr>
</tbody>
</table>
<a href="#section-"></a><br><span class="Bold">Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).<br></span><span class="Bold"><span class="Emphasis"></span></span><br><span class="Bold">Dispense in tight container.</span><br><a href="#section-"></a><a href="#section-"></a><p>Manufactured for: <br>SCHWARZ PHARMA, LLC <br>a subsidiary of 
UCB, Inc. <br>Smyrna, GA 30080</p>
<p>Printed in USA</p>
<p>Rev. 1E 09/2009</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL  -  ROBAXIN   750 MG   TABLET</h1>
<br><p class="First"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5666ece8-9a10-4dcc-a7dc-3cd29df10e28&amp;name=ROBAXIN%20%20750MG%20%20LABEL%20981.jpg"></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROBAXIN 		
					</strong><br><span class="contentTableReg">methocarbamol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-981(NDC:0091-7449)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHOCARBAMOL</strong> (METHOCARBAMOL) </td>
<td class="formItem">METHOCARBAMOL</td>
<td class="formItem">750 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Robaxin;750;SP</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-981-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-981-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-981-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:16590-981-72</td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011011</td>
<td class="formItem">01/20/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>08072c38-1d7b-4d8b-a5e3-6bc14dbadc64</div>
<div>Set id: 5666ece8-9a10-4dcc-a7dc-3cd29df10e28</div>
<div>Version: 1</div>
<div>Effective Time: 20110824</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
